We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.
We aim to save the lives of people who suffer from Chronic Kidney Disease, Diabetes, Heart Failure and Cardiovascular Disease by advancing Cardiovascular-Renal-Metabolic (CVRM) solutions and addressing shared risk factors between these distinct but interrelated disease areas. Our aim is to protect the lives of 50 million people in the next year from the often-devastating consequences of heart failure, cardiovascular, metabolic and renal diseases.
Shared risk factors of CVRM diseases are still often not diagnosed or addressed1-4, and we are committed to help change clinical practice, to address unmet medical needs and create a seamless disease management pathway for patients worldwide.
References
1. Bjornstad et al. Curr Opin Endocrinol Diabetes Obes. 2014 August ; 21(4): 279–286. doi:10.1097/MED.0000000000000074.
2. Narisa Futrakul, Ankanee Chanakul, Prasit Futrakul & Tawatchai Deekajorndech (2015) Early stage of vascular disease and diabetic kidney disease: an underrecognized entity, Renal Failure, 37:8, 1243-1246, DOI: 10.3109/0886022X.2015.1073054
Liviu Segall, Ionut Nistor, and Adrian Covic, “Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review,” BioMed Research International, vol. 2014, Article ID 937398, 21 pages, 2014. https://doi.org/10.1155/2014/937398.
4. Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020